Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YPERP
ADC Name
aU2023308528A1 mAb-vcMMAE (DAR of 4)
Synonyms
AU2023308528A1 mAb-vcMMAE (DAR of 4)
   Click to Show/Hide
Organization
PHEON THERAPEUTICS LTD
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
huCDCP1 (F30-T667 Q525)-8xHis_T3
  Antibody Info 
Antigen Name
Undisclosed
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
ADC-specific functional property(2027 Update)
Binding Affinity
Click To Hide/Show 2 ADC-specific functional property Data
Dissocation Constant (Kd) Binding Target Description Reference
0.604 nM
huCDCP1 (F30-T667Q525)-8xHisT3
In vitro pharmacology was assessed in binding experiments of unconjugated mAb and ADCs to recombinant target antigen ECD. The target antigen was huCDCP1 (F30-T667Q525)-8xHisT3.
[1]
0.604 nM
huCDCP1 (F30-T667Q525)-8xHisT3
In vitro pharmacology was assessed in binding experiments of unconjugated mAb and ADCs to recombinant target antigen ECD. The target antigen was huCDCP1 (F30-T667Q525)-8xHisT3.
[1]
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
< 5
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 20
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
≈ 30
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
> 50
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
> 50
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
> 50
%
Undisclosed Undisclosed
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) < 5% Positive CALU-6 expression (CALU-6+++/++)
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
In Vivo Model NSCLC CALU-6 (lung cancer) model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 20%
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
In Vivo Model MDA-MB-231 (TNBC) model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) ≈ 30% Positive CALU-6 expression (CALU-6+++/++)
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model NSCLC CALU-6 (lung cancer) model
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) > 50% Positive CALU-6 expression (CALU-6+++/++)
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model NSCLC CALU-6 (lung cancer) model
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) > 50%
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model MDA-MB-231 (TNBC) model
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) > 50%
Method Description
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model MDA-MB-231 (TNBC) model
References
Ref 1 Antibody-drug conjugates